Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC

被引：0
|
作者：
Deininger, Michael
Apperley, Jane
Arthur, Christopher Kevin
Chuah, Charles
Hochhaus, Andreas
de Lavallade, Hugues
Lipton, Jeffrey Howard
Lomaia, Elza
McCloskey, James K.
Maness, Lori J.
Mauro, Michael J.
Moiraghi, Beatriz
Pavlovsky, Carolina
Rosti, Gianantonio
Rousselot, Philippe
Sutton, Maria Undurraga
Ren, Xiaowei
Vorog, Alexander
Kantarjian, Hagop M.
Cortes, Jorge E.
机构：
[1] Versiti Blood Res Inst, Milwaukee, WI USA
[2] Imperial Coll London, London, England
[3] Royal North Shore Hosp, St Leonards, NSW, Australia
[4] Duke NUS Med Sch, Singapore Gen Hosp, Singapore, Singapore
[5] Univ Klinikum Jena, Jena, Germany
[6] Kings Coll Hosp NHS Fdn, London, England
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Almazov Natl Med Res Ctr, St Petersburg, Russia
[9] Hackensack Meridian Hlth, John Theurer Canc Ctr, Hackensack, NJ USA
[10] Univ Nebraska Med Ctr, Omaha, NE USA
[11] Mem Sloan Kettering, New York, NY USA
[12] Hosp Jose Maria Ramos Mejia, Buenos Aires, DF, Argentina
[13] Fundaleu, Buenos Aires, DF, Argentina
[14] IRCCS Ist Romagnolo Tumori IRST Dino Amadori, Meldola, FC, Italy
[15] Ctr Hosp Versailles Univ Versailles St Quentin En, Paris, France
[16] Hosp Salvador, Santiago, Chile
[17] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[18] City Hope Natl Med Ctr, Duarte, CA USA
[19] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6501
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).
    Khoury, Hanna Jean
    Mauro, Michael J.
    Matloub, Yousif
    Chen, Tai-Tsang
    Bahceci, Erkut
    Deininger, Michael
    BLOOD, 2009, 114 (22) : 463 - 464
  • [32] CARDIOVASCULAR (CV)-RELATED HOSPITALIZATION IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SIMPLICITY, A PROSPECTIVE OBSERVATIONAL STUDY
    Paquette, R.
    Mauro, M.
    Simonsson, B.
    Abruzzese, E.
    Andorksy, D.
    Hansen, R.
    Subar, M.
    Turner, M.
    Zyczynski, T.
    Mohamed, H.
    Goldberg, S. L.
    HAEMATOLOGICA, 2015, 100 : 437 - 437
  • [33] Detection of T315I in patients with Chronic Myeloid Leukemia by ddPCR preliminary results
    Ivanov, Hristo Y.
    Linev, Aleksandar
    Zheliazkov, Ivan
    Goranova-Marinova, Veselina
    Grudeva-Popova, Zhanet
    Stoyanova, Vili
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 383 - 383
  • [34] Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
    Cortes, Jorge
    Lipton, Jeff H.
    Rea, Delphine
    Digumarti, Raghunadharao
    Chuah, Charles
    Nanda, Nisha
    Benichou, Annie-Claude
    Craig, Adam R.
    Michallet, Mauricette
    Nicolini, Franck E.
    Kantarjian, Hagop
    BLOOD, 2012, 120 (13) : 2573 - 2580
  • [35] Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
    Cortes, Jorge E.
    Sasaki, Koji
    Kim, Dong-Wook
    Hughes, Timothy P.
    Etienne, Gabriel
    Mauro, Michael J.
    Hochhaus, Andreas
    Lang, Fabian
    Heinrich, Michael C.
    Breccia, Massimo
    Deininger, Michael
    Goh, Yeow Tee
    Janssen, Jeroen J. W. M.
    Talpaz, Moshe
    de Soria, Valle Gomez Garcia
    le Coutre, Philipp
    Deangelo, Daniel J.
    Damon, Andrea
    Cacciatore, Silvia
    Polydoros, Fotis
    Agrawal, Nithya
    Rea, Delphine
    LEUKEMIA, 2024, 38 (07) : 1455 - 1468
  • [36] Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation
    Ferri, Cristian A.
    Bianchini, Michele
    Bengio, Raquel M.
    Moiraghi, Elena B.
    Gonzalez, Mariana S.
    Noriega, Maria F.
    Larripa, Irene B.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) : 270 - 272
  • [37] Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
    Mueller, Martin C.
    Cortes, Jorge
    Chuah, Charles
    DeAngelo, Daniel J.
    Deininger, Michael
    Guilhot, Francois
    Hughes, Timothy
    Nicolini, Franck E.
    Pinilla-Ibarz, Javier
    Rea, Delphine
    Rosti, Gianantonio
    Shah, Neil P.
    Talpaz, Moshe
    Lu, Vickie
    Padukkavidana, Thihan
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S336 - S337
  • [38] Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US
    Mauro, Michael J.
    McGarry, Lisa J.
    Lustgarten, Stephanie
    Huang, Hui
    BLOOD, 2016, 128 (22)
  • [39] Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial
    Cortes, J. E.
    Khoury, H. J.
    Corm, S.
    Nicolini, F.
    Schenk, T.
    Jones, D.
    Hochhaus, A.
    Craig, A. R.
    Humphriss, E.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era
    Haddad, Fadi G. G.
    Sasaki, Koji
    Bidikian, Aram
    Issa, Ghayas C. C.
    Kadia, Tapan
    Jain, Nitin
    Alvarado, Yesid
    Short, Nicholas J. J.
    Pemmaraju, Naveen
    Loghavi, Sanam
    Patel, Keyur P. P.
    Kanagal-Shamanna, Rashmi
    Yilmaz, Musa
    Masarova, Lucia
    Jabbour, Elias
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (10) : 1619 - 1626
12345